Publication date: Sep 04, 2024
The monoclonal antibody therapies bamlanivimab (BAM) + etesevimab (ETE) received emergency use authorization (EUA) from the US Food and Drug Administration (February 9, 2021) for treatment of mild-to-moderate COVID-19. The EUA of BAM + ETE was revoked (December 14, 2023) due to the high prevalence of BAM + ETE-resistant variants of SARS-CoV-2. Efficacy and safety of 700/1400 mg and 2800/2800 mg BAM + ETE are well established and published; however, efficacy and safety of 350/700 mg BAM + ETE have not been disclosed to date. This portion of phase 3, BLAZE-1 trial (J2X-MC-PYAB) enrolled patients (between June 17, 2020 and April 9, 2021) with mild-to-moderate COVID-19 within 3 days of laboratory diagnosis of SARS-CoV-2 infection. In total, 354 patients with at least one risk factor for severe COVID-19 were enrolled, randomized (2:3), and infused with placebo (N = 141) or 350/700 mg BAM + ETE (N = 213), over ~ 8 min. Primary endpoint was to assess proportion of patients with persistently high SARS-CoV-2 viral load (PHVL) (log viral load > 5. 27) 7 days after infusion. Patients were aged (mean) 53 years, 49. 7% female, and 82. 7% White. Seven days after drug infusion, 10. 8% (95% confidence interval: 6. 6, 15. 0; p
Concepts | Keywords |
---|---|
1400mg | Bamlanivimab |
Food | BLAZE-1 |
June | Clinical trial |
Severe | COVID-19 |
Etesevimab | |
Treatment |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | COVID-19 |
disease | MESH | emergency |
pathway | REACTOME | SARS-CoV-2 Infection |
disease | MESH | viral load |